{"drugs":["Marqibo","Vincristine Sulfate Liposome"],"mono":{"0":{"id":"930272-s-0","title":"Generic Names","mono":"Vincristine Sulfate Liposome"},"1":{"id":"930272-s-1","title":"Dosing and Indications","sub":[{"id":"930272-s-1-4","title":"Adult Dosing","mono":"<ul><li>vinCRIStine sulfate LIPOSOME has different dosing than vinCRIStine sulfate injection; verify drug name and dose prior to preparation and administration<\/li><li>fatal if administered by routes other than IV; deaths have occurred with intrathecal administration<\/li><li>safety and effectiveness have not established in geriatric patients.<\/li><li><b>Acute lymphoid leukemia, Philadelphia chromosome-negative, relapsed or progressed:<\/b> 2.25 mg\/m(2) IV over 1 hour once every 7 days; use actual BSA<\/li><\/ul>"},{"id":"930272-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not established in pediatric patients."},{"id":"930272-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic toxicity:<\/b> reduce dose or interrupt therapy<\/li><li><b>fatigue, severe:<\/b> consider dose delay, reduce, or discontinue<\/li><li><b>myelosuppression, grade 3 or 4:<\/b> consider a dose modification or reduction<\/li><li><b>peripheral neuropathy, initial grade 3:<\/b> interrupt therapy until recovery to grade 1 or 2, then reinitiate with reduced dose of 2 mg\/m(2); if grade 3 persists or grade 4 occurs, then discontinue therapy<\/li><li><b>peripheral neuropathy, persistent grade 2:<\/b> interrupt therapy until recovery to grade 1 or 2, then reinitiate with reduced dose of 2 mg\/m(2); if grade 2 persists after 1st dose reduction, interrupt therapy for up to 7 days until recovery to grade 1, then reinitiate with 2nd reduced dose of 1.825 mg\/m(2); if grade 2 persists after 2nd dose reduction, interrupt therapy for up to 7 days until recovery to grade 1, then reinitiate with 3rd reduced dose of 1.5 mg\/m(2); if grade 3 or 4 occurs at any time, discontinue therapy<\/li><\/ul>"},{"id":"930272-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Acute lymphoid leukemia, Philadelphia chromosome-negative, relapsed or progressed<br\/>"}]},"2":{"id":"930272-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Suspension)<\/b><br\/>For intravenous use only. Fatalities have occurred when given by other routes, including intrathecal administration. VinCRIStine sulfate liposome injection has different dosage recommendations than vinCRIStine sulfate injection. Verify drug name and dose before preparation and administration to avoid overdosage.<br\/>"},"3":{"id":"930272-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930272-s-3-9","title":"Contraindications","mono":"<ul><li>demyelinating conditions, including Charcot-Marie-Tooth syndrome<\/li><li>hypersensitivity to vinCRIStine sulfate or other components of the product<\/li><li>intrathecal administration; fatalities have been reported<\/li><\/ul>"},{"id":"930272-s-3-10","title":"Precautions","mono":"<ul><li>for IV use only; fatal if given by other routes, including intrathecal administration<\/li><li>bowel obstruction, ileus, colonic pseudoobstruction, and constipation have been reported; prophylactic bowel regimen recommended<\/li><li>concomitant use with potent P-glycoprotein inhibitors or inducers should be avoided<\/li><li>concomitant use with strong CYP3A inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital, St. John's Wort) should be avoided<\/li><li>concomitant use with strong CYP3A inhibitors (eg, ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin) should be avoided<\/li><li>extravasation causing tissue injury has occurred; discontinue infusion and consider local treatment if extravasation is suspected<\/li><li>fatigue, severe, has been reported; dose adjustment or discontinuation may be required<\/li><li>hepatic toxicity, sometimes fatal, and elevated AST levels have been reported; monitoring recommended; dose reduction or interruption may be required<\/li><li>myelosuppression has occurred; monitoring recommended; dose adjustment may be required.<\/li><li>neurologic toxicity (peripheral motor and sensory, central, and autonomic neuropathy) has been reported, with greater risk in patients with preexisting neuromuscular disorders or with concomitant use of neurotoxic drugs; monitoring recommended; dose adjustment, delay, or withdrawal may be required<\/li><li>orthostatic hypotension may occur<\/li><li>tumor lysis syndrome may occur; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930272-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"930272-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930272-s-4","title":"Drug Interactions","sub":[{"id":"930272-s-4-13","title":"Contraindicated","mono":"<ul><li>Boceprevir (theoretical)<\/li><li>Rotavirus Vaccine, Live (established)<\/li><\/ul>"},{"id":"930272-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Amiodarone (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Asparaginase (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Bosutinib (theoretical)<\/li><li>Captopril (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Filgrastim (probable)<\/li><li>Fluconazole (probable)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Itraconazole (established)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Posaconazole (probable)<\/li><li>Primidone (theoretical)<\/li><li>Quercetin (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinupristin (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Saquinavir (theoretical)<\/li><li>Sargramostim (probable)<\/li><li>Simeprevir (theoretical)<\/li><li>Smallpox Vaccine (established)<\/li><li>St John's Wort (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tocophersolan (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Typhoid Vaccine (established)<\/li><li>Ulipristal (theoretical)<\/li><li>Valspodar (probable)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Verapamil (theoretical)<\/li><li>Voriconazole (probable)<\/li><li>Warfarin (probable)<\/li><li>Yellow Fever Vaccine (established)<\/li><li>Zidovudine (theoretical)<\/li><\/ul>"},{"id":"930272-s-4-15","title":"Moderate","mono":"<ul>Nifedipine (probable)<\/ul>"}]},"5":{"id":"930272-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Constipation (57%), Decrease in appetite (33%), Diarrhea (37%), Nausea (52%)<\/li><li><b>Hematologic:<\/b>Anemia (34%), Febrile neutropenia (38%)<\/li><li><b>Neurologic:<\/b>Insomnia (32%), Peripheral nerve disease (39%)<\/li><li><b>Other:<\/b>Fatigue (41%), Fever (43%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest (6%), Hypotension, Grade 3 or greater (6%)<\/li><li><b>Gastrointestinal:<\/b>Constipation, Grade 3 or greater (4.8%), Pseudo-obstruction of gastrointestinal tract, Grade 3 or greater<\/li><li><b>Hematologic:<\/b>Anemia, Grade 3 or greater (16.9%), Febrile neutropenia, Grade 3 or greater (31.3%), Neutropenia, Grade 3 or greater (18.1%), Thrombocytopenia, Grade 3 or greater (16.9%)<\/li><li><b>Hepatic:<\/b>AST\/SGOT level raised, Grade 3 or greater (6% to 11%), Hepatotoxicity<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction, Septic shock, Grade 3 or greater (6%), Staphylococcal infectious disease, Grade 3 or greater (6%)<\/li><li><b>Neurologic:<\/b>Peripheral motor neuropathy, Grade 3 or greater (16.7% to 31%)<\/li><li><b>Respiratory:<\/b>Pneumonia, Grade 3 or greater (8.4%), Respiratory distress, Grade 3 or greater (6%), Respiratory failure, Grade 3 or greater (4.8%)<\/li><li><b>Other:<\/b>Fever, Grade 3 or greater (14.5%), Tumor lysis syndrome<\/li><\/ul>"},"6":{"id":"930272-s-6","title":"Drug Name Info","sub":{"0":{"id":"930272-s-6-17","title":"US Trade Names","mono":"Marqibo<br\/>"},"2":{"id":"930272-s-6-19","title":"Class","mono":"Mitotic Inhibitor<br\/>"},"3":{"id":"930272-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930272-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930272-s-7","title":"Mechanism Of Action","mono":"VinCRIStine  sulfate, the active agent in the sphingomyelin\/cholesterol liposome-encapsulated formulation of vinCRIStine sulfate, exhibits cell cycle-specificity. It binds to tubulin, with resultant microtubule depolymerization and arrests the cell growth in metaphase; apoptosis of cells in mitosis has been observed. Cytotoxic activity has been shown to increase when exposure to tumor cells is prolonged, favoring use of the drug in a liposomal formulation.<br\/>"},"8":{"id":"930272-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"930272-s-8-23","title":"Absorption","mono":"Bioavailability, IV: delayed, compared with non-liposomal vinCRIStine sulfate <br\/>"},"3":{"id":"930272-s-8-26","title":"Excretion","mono":"Total body clearance: 345 mL\/hr <br\/>"}}},"9":{"id":"930272-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use the proper procedures for handling and disposal of vinCRIStine sulfate liposome<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>requires 60 to 90 minutes of monitored preparation utilizing kit supplied by manufacturer<\/li><li>kits are supplied with each vial; do NOT reuse kit components<\/li><li>do NOT mix with other drugs<\/li><li>do NOT use in-line filters<\/li><li>outside sterile area prepare water bath of at least 8 cm (3.2 inches) to 63 to 67 degrees C and maintain temperature with calibrated thermometer<\/li><li>in a biological safety cabinet vent sodium phosphate injection vial with sterile venting needle equipped with a 0.2 micron filter or other suitable venting device with needle positioned well above liquid level<\/li><li>withdraw 1 mL of sphingomyelin\/cholesterol liposome injection and add to the sodium phosphate injection vial<\/li><li>withdraw 5 mL of vinCRIStine sulfate injection and add to the sodium phosphate injection vial<\/li><li>remove venting needle and gently invert vial 5 times to mix; do NOT shake<\/li><li>fit flotation ring around vial and add to water bath for 10 minutes using the calibrated timer and with temperature maintained at 63 to 67 degrees C (outside sterile area)<\/li><li>record the start and final constitution time and the start and final water temperature on the overlabel<\/li><li>remove from water bath and gently invert vial 5 times to mix; do NOT shake<\/li><li>leave vial at controlled room temperature (15 to 30 degrees C or 59 to 86 degrees F) for 30 minutes and no longer than 12 hours; vinCRIStine sulfate liposome contains 5 mg\/31 mL<\/li><li>in a biological safety cabinet withdraw a volume of D5W or NS from a 100 mL bag corresponding to the patient's dose and inject the dose of vinCRIStine sulfate liposome into the infusion bag to a final volume of 100 mL<\/li><li>complete the administration within 12 hours of the initiation of preparation<\/li><li>administer ONLY by IV route over 1 hour<\/li><li>extravasation causes tissue injury, administer through a secure and free-flowing venous access line<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930272-s-10","title":"Monitoring","mono":"<ul><li>disease response indicates efficacy<\/li><li>CBC; prior to each dose  with differential<\/li><li>liver function tests; throughout treatment<\/li><li>signs of tumor lysis syndrome<\/li><li>neurologic exam; before and during therapy<\/li><\/ul>"},"11":{"id":"930272-s-11","title":"How Supplied","mono":"<b>Marqibo<\/b><br\/>Intravenous Suspension: 0.16 MG\/ML<br\/>"},"13":{"id":"930272-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to avoid driving or operating heavy machinery until drug effects are realized, as drug may cause peripheral neuropathy or fatigue.<\/li><li>Recommend female patient use reliable contraception to avoid pregnancy during therapy.<\/li><li>Counsel patient to seek medical advice if symptoms of constipation develop.<\/li><li>Drug may cause insomnia, nausea, diarrhea, anemia, or febrile neutropenia.<\/li><li>Advise patient to immediately report extravasation injury (irritation, burning sensation at infusion site) or symptoms of myelosuppression.<\/li><li>Warn patient to report new\/worsening symptoms of neuropathy (hypoesthesia, hyperesthesia, paresthesia, neuralgia, burning sensation).<\/li><\/ul>"}}}